In addition, HMGB1 released from IRE-treated tumor cells have been shown to reprogram TAMs from immune-suppressive (M2) to immune-promoting (M1) phenotypes [88], thereby increasing the M1/M2 ratio in the TME and the periphery [96]. The gene discussed is HMGB1; the disease is neoplasm.